MedTrace Logo

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

NCT02566759 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2021-06-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK) of single and multiple rising doses of TAK-831 in healthy participants.

Conditions

  • Schizophrenia, Cerebellar Ataxia

Interventions

DRUG

TAK-831 Oral Suspension

TAK-831 oral suspension.

DRUG

TAK-831 Placebo

TAK-831 placebo-matching oral suspension.

DRUG

TAK-831 Tablet

TAK-831 tablet.

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Neurocrine Biosciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-23
Primary Completion
2016-06-09
Completion
2016-07-12

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02566759 on ClinicalTrials.gov